Mody, Rajen <br/><br/>
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.  [electronic resource] 

 -  The Lancet. Oncology  07 2017 
 - 946-957 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(17)30355-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Alanine Transaminase--blood<br/>Anemia--chemically induced<br/>Antibodies, Monoclonal--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Camptothecin--administration & dosage<br/>Child<br/>Child, Preschool<br/>Dacarbazine--administration & dosage<br/>Disease-Free Survival<br/>Fever--chemically induced<br/>Ganglioneuroblastoma--diagnostic imaging<br/>Gene Amplification<br/>Granulocyte-Macrophage Colony-Stimulating Factor--administration & dosage<br/>Humans<br/>Hypokalemia--chemically induced<br/>Hypoxia--chemically induced<br/>Infant<br/>Infections--chemically induced<br/>Irinotecan<br/>N-Myc Proto-Oncogene Protein--genetics<br/>Neoplasm Recurrence, Local--diagnostic imaging<br/>Neuroblastoma--diagnostic imaging<br/>Neutropenia--chemically induced<br/>Pain--chemically induced<br/>Response Evaluation Criteria in Solid Tumors<br/>Retreatment<br/>Sirolimus--administration & dosage<br/>Survival Rate<br/>Temozolomide<br/>Thrombocytopenia--chemically induced